論文 - 盛武 浩
-
[Treatment outcome of non-Hodgkin lymphoma in childhood: KYCCSG NHL-89, 96]. 査読あり
Fukano R., Suminoe A., Matsuzaki A., Inada H., Nagatoshi Y., Ishii E., Nakayama H., Kawakami K., Moritake H., Yanai F., Itonaga N., Suenobu S., Kikuchi M., Okamura J., Kawano Y.
[Rinshō ketsueki] The Japanese journal of clinical hematology 53 ( 11 ) 1898 - 1905 2012年11月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：[Rinshō ketsueki] The Japanese journal of clinical hematology
Two consecutive treatment protocols, NHL-89 and NHL-96, for pediatric diffuse large cell lymphoma (DLC) and lymphoblastic lymphoma (LBL) were conducted between March 1989 and December 2004 by Kyushu-Yamaguchi Children's Cancer Study Group. Forty-two patients (DLC: 15, LBL: 27) and 34 patients (DLC: 8, LBL: 26) were enrolled in NHL-89 and NHL-96, respectively. DLC patients received induction therapy of high-dose methotrexate (MTX) followed by repeated administration of intermediate MTX. LBL patients received a 4-drug induction followed by intensification, consolidation with cranial radiotherapy (15 to 24Gy), and maintenance. The maintenance phase consisted of multiple drug treatment; including prednisolone, vincristine, cyclophosphamide, and 6-mercaptopurine. With a median follow-up of 150 months for NHL-89 and 90.5 months for NHL-96, the estimated event-free survival at 5 years are 76.2±6.6% and 67.7±8.0%, respectively. Both studies improved the prognosis of DLC and LBL over our previous study of NHL-858.
-
Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan 査読あり
Matsunaga T, Yamashita K, Kubuki Y, Toyama T, Imataki O, Maeda K, Kawano N, Satou S, Kawano H, Ishizaki J, Yoshida S, Kameda T, Sasaki T, Sekine M, Kamiunten A, Taniguchi Y, Hidaka T, Katayose K, K-Shimoda H, Shide K, Yamamoto S, Moritake H, Nunoi H, Maki
International Journal of Hematology 96 ( 3 ) 342 - 349 2012年9月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Taga T., Saito A., Kudo K., Tomizawa D., Terui K., Moritake H., Kinoshita A., Iwamoto S., Nakayama H., Takahashi H., Tawa A., Shimada A., Taki T., Kigasawa H., Koh K., Adachi S.
Blood 120 ( 9 ) 1810 - 1815 2012年8月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Blood
Myeloid leukemia in Down syndrome (ML-DS) is associated with good response to chemotherapy and favorable prognosis. Because little research has been focused on refractory/relapsed (R/R) cases, we conducted a retrospective analysis for R/R ML-DS. Among ML-DS patients diagnosed between 2000 and 2010 in Japan, 26 relapsed (25 in the BM and 1 in the skin), and 3 refractory patients were enrolled. The male/female ratio was 18/11. The median age at initial diagnosis of ML-DS was 2 years, and the median time to relapse was 8.6 months. Each patient initially had been treated with ML-DS-specific protocols. Thirteen of the 26 patients achieved complete remission with various kinds of reinduction chemotherapies; 2 of 8 survived without further recurrence after receiving allogeneic hematopoietic stem cell transplantation, and 4 of 5 maintained complete remissions with chemotherapy alone. Treatment failures mostly were associated with disease progression rather than treatment-related toxicities. The 3-year OS rate was 25.9% ± 8.5%. A longer duration from initial diagnosis to relapse was a significant favorable prognostic factor (P < .0001). We conclude that clinical outcome for patients with R/R ML-DS generally are unfavorable, even in those receiving hematopoietic stem cell transplantation. Novel methods to identify poor prognostic factors for ML-DS are necessary. © 2012 by The American Society of Hematology.
-
小児がん患者における病気のとらえ方の検討 査読あり
武井 優子, 尾形 明子, 平井 啓, 小澤 美和, 盛武 浩, 真部 淳, 鈴木 伸一
心身医学 = Japanese journal of psychosomatic medicine 52 ( 7 ) 638 - 645 2012年7月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in child with Down syndrome: Successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease 査読あり
Moritake H, Yamada A, Kimoto Y, Sawa D, Shimonodan H, Nunoi H
Am J Hematol 87 ( 4 ) 447 - 450 2012年4月
担当区分：筆頭著者 掲載種別：研究論文（学術雑誌）
-
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in child with Down syndrome: Successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease. 査読あり
Moritake H.＊, Yamada A., Kimoto Y., Sawa D., Shimonodan H., Nunoi H
American Journal of Hematology 87 ( 4 ) 457 - 450 2012年4月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Concomitant transient erythroblastopenia of childhood with neonatal hepatitis. 査読あり
Moritake H, Hidaka F, Kamimura S, Kojima H, Shimonodan H, Nunoi H.
Pediatrics International 54 ( 1 ) 147 - 150 2012年2月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. 査読あり
Fujimoto T, Andoh T, Sudo T, Fujita I, Imabori M, Moritake H, Sugimoto T, Sakuma Y, Takeuchi T, Sonobe H, Epstein AL, Akisue T, Kirihata M, Kurosaka M, Fukumori Y, Ichikawa H.
Applied Radiation Isotopes 69 ( 12 ) 1713 - 1716 2011年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Andoh T., Fujimoto T., Sudo T., Fujita I., Imabori M., Moritake H., Sugimoto T., Sakuma Y., Takeuchi T., Kawabata S., Kirihata M., Akisue T., Yayama K., Kurosaka M., Miyatake S., Fukumori Y., Ichikawa H.
Applied Radiation and Isotopes 69 ( 12 ) 1721 - 1724 2011年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Applied Radiation and Isotopes
Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10 B (45-74ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of l-BPA-fructose complex (500mg BPA/kg). © 2011 Elsevier Ltd.
-
C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC 査読あり
Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H
Am J Hematol 86 ( 1 ) 75 - 78 2011年1月
担当区分：筆頭著者 掲載種別：研究論文（学術雑誌）
-
Moritake H., Shimonodan H., Marutsuka K., Kamimura S., Kojima H., Nunoi H.
American Journal of Hematology 86 ( 1 ) 75 - 78 2011年1月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
P1-12 小児がん患者における病気のとらえ方と退院後の困難の関連性の検討(一般演題(ポスター発表),切れる最新の理論と途切れない地道な実践) 査読あり
武井 優子, 尾形 明子, 小澤 美和, 盛武 浩, 真部 淳, 平井 啓, 鈴木 伸一
日本行動療法学会大会発表論文集 ( 36 ) 164 - 165 2010年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人日本認知・行動療法学会
-
Randomized trial to compare LSA2L2 type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia. 共著 査読あり
Nagatoshi Y, Moritake H, 他
Pediatr. Blood Cancer 55 ( 2 ) 239 - 247 2010年8月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Cytomagalovirus infection mimicking juvenile myelomonocytic leukemia showing hypersensitivity to granulocyte-macrophage colony stimulating factor.（共著） 査読あり
Moritake H. 他
Pediatric Blood & Cancer 53 ( 7 ) 1324 - 1326 2009年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Cytomegalovirus infection mimicking juvenile myelomonocytic leukemia showing hypersensitivity to granulocyte-macrophage colony stimulating factor 査読あり
Moritake H, Ikeda T, Manabe A, Kamimura S, Nunoi H
Pediatr Blood Cancer 53 ( 7 ) 1324 - 1326 2009年12月
担当区分：筆頭著者 掲載種別：研究論文（学術雑誌）
-
PP-196 Xp11.2転座/TFE3融合遺伝子関連腎癌の1例(腎腫瘍/症例2,一般演題ポスター,第97回日本泌尿器科学会総会) 査読あり
向井 尚一郎, 上村 敏雄, 田中 弘之, 盛武 浩, 長野 正史, 蓮井 良浩
日本泌尿器科学会雑誌 100 ( 2 ) 2009年
-
Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity 査読あり
Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E, Ihle JN.
Mol Cell Biol 28 ( 5 ) 1792 - 1801 2008年3月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
眼窩腫瘍を初発症状とした小児の急性巨核芽球性白血病の１例 査読あり
白坂陽子,中馬秀樹,直井信久,満木ひとみ,盛武 浩
眼科 48 511 - 516 2006年
記述言語：日本語 掲載種別：症例報告
-
Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group 査読あり
Matsuzaki A, Nagatoshi Y, Inada H, Nakayama H, Yanai F, Ayukawa H, Kawakami K, Moritake H, Suminoe A, Okamura J
Pediatr Blood Cancer 45 ( 2 ) 111 - 120 2005年8月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Kuroda H., Moritake H., Sawada K., Kuwahara Y., Imoto I., Inazawa J., Sugimoto T.
Cancer Genetics and Cytogenetics 158 ( 2 ) 172 - 179 2005年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Cancer Genetics and Cytogenetics
Malignant rhabdoid tumors (MRT) of the liver are rare. A few liver MRT cell lines have been established but none has been characterized in detail. Here we describe a new MRT cell line from the liver, which is designated MP-MRT-AN, and describe it in detail. Immunohistochemical assays detected the expression of vimentin and cytokeratin but they were negative for neurofilament, desmin, α-smooth muscle actin, α-sarcomeric actin, and smooth muscle myosin heavy chains SM1 and SM2. RT-PCR assays revealed that this cell line did not express smooth muscle myosin heavy chain isoforms or MyoD1. No aberration was identified in 22q by G-banded analysis; however, the hSNF5/INI1 gene, a suppressor gene of MRT that maps to 22q11.2, was homozygously deleted from exons 1 to 5 in this cell line. Furthermore, the expression of another tumor suppressor gene, p16 (CDKN2A), was not detected by RT-PCR. This raises the possibility that the aggressive phe notype of malignant rhabdoid tumors is caused by the loss of two or more tumor suppressor genes. © 2005 Elsevier Inc. All rights reserved.